Addressing Toxicities of BCMA-Targeted Therapy for Multiple Myeloma
Adam Cohen, MD, discusses the adverse events of concern associated with B-cell maturation antigen–targeted therapies for relapsed/refractory multiple myeloma.
Identifying Patients With R/R MM Who Should Receive CAR T-Cell Therapy
Adam Cohen, MD, discusses when patients should receive chimeric antigen receptor T-cell therapies for relapsed/refractory multiple myeloma.
Behind the FDA Approvals of BCMA-Directed Therapies for Multiple Myeloma
Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.
